RxDoctor Payments Data

Angela Murno, APRN

Nurse Practitioner · Torrington, CTNPI 1700990264

Payments from drug & device makers

$3,265in general payments, 2019–2025

Across 185 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$921
  • Takeda Pharmaceuticals U.S.A., Inc.$438
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$301
  • Bristol Myers Squibb$278
  • Johnson & Johnson$213
  • Sanofi$157
  • plus $956 from 17 others

What the payments were for

  • Food & beverage$3,23499%
  • Education$311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,265 in reported general payments places this provider in the 90th percentile of 1,162 nurse practitioner providers in Connecticut.

See all nurse practitioner providers in Connecticut

Medicare billing

Part B allowed, 2024
$27,052
Medicare patients
213
Services billed
256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab24$658,293
Humira(Cf) PenAdalimumab26$360,095
LinzessLinaclotide144$134,809
Dupixent PenDupilumab14$104,357
CreonLipase/Protease/Amylase33$90,603
Mesalamine70$46,413
Dexlansoprazole DrDexlansoprazole55$28,859
NexiumEsomeprazole Magnesium18$26,863
MotegrityPrucalopride Succinate18$19,208
Budesonide ErBudesonide12$16,172
TrulancePlecanatide20$11,531
MovantikNaloxegol Oxalate20$9,888
Pantoprazole Sodium485$6,741
SutabSod Sulf/Pot Chloride/Mag Sulf33$5,375
Omeprazole248$4,923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$213$658,29324 claims
AbbVieLinzess, Creon$921$225,413177 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$438$19,20818 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$301$11,53120 claims
Braintree Laboratories, Inc.Sutab$39$5,37533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,162 nurse practitioner providers in Connecticut.

Other nurse practitioner in Torrington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →